Related Experiment Video
Updated: May 22, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Endometrial cancer
Kimberly K Leslie1, Kristina W Thiel, Michael J Goodheart
1Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. kimberly-leslie@uiowa.edu
Abstract:
Despite the questions and barriers, the incorporation of molecular therapy into treatment regimens in endometrial cancer is an exciting area of investigation with the potential to improve outcomes. Outside of the development of a reliable screening test for endometrial cancer, converting the disease to a chronic state and improving progression-free survival is our best hope to reverse the concerning trend of decreasing 5-year survival for this disease.
Insights
Molecular therapy shows promise for endometrial cancer treatment, aiming to improve patient outcomes. The best strategy involves managing the disease as chronic and enhancing progression-free survival.
Area of Science:
- Oncology
- Molecular Biology
- Gynecologic Oncology
Background:
- Endometrial cancer presents challenges in treatment and survival rates.
- Current therapeutic strategies have limitations in improving long-term outcomes.
- There is a need for innovative approaches to manage endometrial cancer effectively.
Purpose of the Study:
- To explore the potential of molecular therapy in endometrial cancer treatment.
- To investigate strategies for improving progression-free survival in endometrial cancer patients.
- To assess the feasibility of managing endometrial cancer as a chronic condition.
Main Methods:
- Review of current literature on molecular therapies for endometrial cancer.
- Analysis of treatment regimens incorporating targeted molecular agents.
- Evaluation of progression-free survival data in relevant clinical trials.
Main Results:
- Molecular therapy integration is a promising area for endometrial cancer.
- Managing endometrial cancer as a chronic illness offers a potential survival benefit.
- Improved progression-free survival is a key objective for reversing declining survival trends.
Conclusions:
- Molecular therapies hold significant potential for advancing endometrial cancer care.
- Shifting focus to chronic disease management and progression-free survival is crucial.
- Further research is warranted to overcome barriers and optimize molecular therapy incorporation.
Related Concept Videos
01:24Disorders of the Female Reproductive System
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...